Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Sodium chloride dissociates in body fluids into sodium and chloride ions, which are major determinants of extracellular fluid osmolality and volume. It maintains electrolyte balance, nerve impulse transmission, and muscle contraction.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous: 0.9% sodium chloride (normal saline) infusion at 50-100 mL/hour for maintenance; dose depends on indication (e.g., 500-1000 mL bolus for hypovolemia). Maximum rate: 1 L/hour in emergencies.
None Documented
Clinical Note
moderateSodium chloride + Tolvaptan
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Clinical Note
moderateLithium cation + Sodium chloride
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Variable and distribution-dependent; for acute changes, distribution half-life ~20 minutes; terminal half-life ~8-12 hours for total body sodium adjustment, clinically relevant for electrolyte correction
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily renal (>90%) via glomerular filtration and tubular reabsorption; negligible biliary/fecal elimination (<1%)
Category C
Category A/B
Electrolyte
Electrolyte